**EXHIBIT 99.1**

**LDR HOLDING CORPORATION REPORTS FIRST QUARTER 2014 RESULTS**

***First quarter revenue increased 20.2% year-over-year to $31.1 million***

AUSTIN, Texas, May 7, 2014 - LDR Holding Corporation (NASDAQ: LDRH), a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders, today reported its financial results for the first quarter of 2014.

***First Quarter 2014 Revenue Highlights***

* Total revenue for the quarter ended March 31, 2014 increased 20.2% to $31.1 million, compared to $25.8 million for the quarter ended March 31, 2013.
* Revenue for the first quarter of 2014 from exclusive technology products grew 26.9% to $26.5 million, compared to $20.9 million for the first quarter of 2013.
* Revenue in the United States increased 24.6% to $23.2 million in the quarter, compared to $18.6 million in the first quarter of 2013, and represented 74.6% of total revenue.
* International revenue increased 9.0% during the first quarter of 2014 to $7.9 million, representing 25.4% of total revenue.

In the first quarter of 2014, LDR's revenue from exclusive technology products grew 26.9% to $26.5 million while revenue from traditional fusion products decreased 7.9% to $4.6 million. Revenue from sales of the Company's exclusive cervical products grew 34.0% in the first quarter of 2014 to $17.7 million, compared with $13.2 million in the first quarter of 2013, due principally to the growth of Mobi-C. Additionally, revenue from LDR's exclusive lumbar products in the first quarter increased 14.8% to $8.8 million compared with $7.7 million in the first quarter of 2013, led by revenue growth of the Avenue L lateral lumbar fusion interbody device. Along with growth in LDR’s non-fusion products led by Mobi-C, LDR’s VerteBRIDGE fusion products for both the cervical and lumbar lines continues to grow, in part, because surgeons who are trained to use Mobi-C can be introduced to the balance of LDR's exclusive technology product lines for use in surgical cases where fusion is appropriate.

Christophe Lavigne, President and Chief Executive Officer of LDR, commented, “Our exclusive technology products grew at a strong rate again this quarter, aided by the availability of Mobi-C in the U.S. market, and higher revenues in both our cervical and lumbar product lines. We were very pleased that the American Medical Association granted a Category 1 CPT code for two-level cervical disc replacement, effective January 1, 2015. This is an important milestone for LDR as it will provide surgeons with certainty as to the payment rate for the two-level procedures they perform and will facilitate Mobi-C reimbursement. We are gratified by the strong interest among spine surgeons in education and training sessions for Mobi-C, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. We are continuing to train surgeons to use Mobi-C and are actively working with their hospitals to finalize the access and pricing necessary to conduct their initial cases. In the sales area, the availability of Mobi-C and its superiority claim has been quite attractive to independent sales agencies which otherwise do not have access to cervical disc replacement devices.”

Gross profit for the first quarter of 2014 was $25.8 million and gross margin was 83.1%, compared to a gross profit of $21.5 million and gross margin of 83.4% for the first quarter of 2013.

Net loss for the first quarter of 2014 totaled $3.5 million, or $0.15 per share, compared to a net loss of $1.9 million, or $0.41 per share, for the same quarter a year ago.

Adjusted EBITDA for the first quarter of 2014 was $(1.0) million compared to an adjusted EBITDA of $0.7 million for the first quarter of 2013.

Mr. Lavigne added, “Our exclusive technology products uniquely meet patient and surgeon needs and represent a significant sales opportunity in today’s spine marketplace. We are continuing to take full advantage of this opportunity through investments in surgeon training and education, our reimbursement and corporate organizations, and our sales and marketing infrastructure. We expect these investments will enhance LDR's growth profile and long-term competitive position.”

**Balance Sheet and Liquidity**

As of March 31, 2014, LDR had $49.8 million in cash and cash equivalents, $71.6 million in working capital and $23.2 million in debt.

**Conference Call**

LDR Holding Corporation will host a conference call today at 5:00 p.m. Eastern Time to discuss its first quarter 2014 financial results. The conference call will be available to interested parties through a live audio webcast available through LDR's website at www.ldr.com. Those without internet access may join the call from within the United States by dialing (877) 312-5637; outside the United States, by dialing (253) 237-1149.

A telephone replay will be available for two weeks following the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants. When prompted, please enter the replay pin number 40465782. For those who are not available to listen to the live webcast, the call will be archived for 90 days on LDR Holding's website.

**Forward-Looking Statements**

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief or current expectations of LDR and members of its management team with respect to LDR's future business operations as well as the assumptions upon which such statements are based. Forward-looking statements include specifically, but are not limited to, LDR's market opportunities, growth, future products, market acceptance of its products, sales and financial results and such statements are subject to risks and uncertainties such as the timing and success of new product introductions, physician acceptance, endorsement, and use of LDR's products, regulatory matters, competitor activities, changes in and adoption of reimbursement rates, potential product recalls, effects of global economic conditions and changes in foreign currency exchange rates. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in LDR's Risk Factors disclosure in its Annual Report on Form 10-K, filed on March 4, 2014, and in LDR's other filings with the SEC. LDR disclaims any responsibility to update any forward-looking statements.

**About LDR Holding Corporation**

LDR Holding Corporation is a global medical device company focused on designing and commercializing novel and proprietary surgical technologies for the treatment of patients suffering from spine disorders. LDR's primary products are based on its exclusive VerteBRIDGE fusion and Mobi non-fusion technology platforms and are designed for applications in the cervical and lumbar spine. These technologies enable products that are less invasive, provide greater intra-operative flexibility, offer simplified surgical techniques and promote improved clinical outcomes for patients as compared to existing alternatives. LDR recently received approval from the U.S. Food and Drug Administration (FDA) for the Mobi-C cervical disc replacement device, the first and only cervical disc replacement device to receive FDA approval to treat both one-level and two-level cervical disc disease. For more information regarding LDR Holding, visit www.ldr.com.

**Use of Non-GAAP Financial Measures**

To supplement LDR's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), LDR uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Management defines Adjusted EBITDA as operating income (loss) plus depreciation and amortization and stock-based compensation expense. The Company presents Adjusted EBITDA because management believes it is a useful indicator of operating performance. LDR's management uses Adjusted EBITDA principally as a measure of operating performance and believes that Adjusted EBITDA is useful to investors because it is frequently used by securities analysts, investors and other interested parties in their evaluation of the operating performance of companies in industries similar to LDR. Management also uses Adjusted EBITDA for planning purposes, including the preparation of the annual operating budget and financial projections.

A reconciliation of the non-GAAP financial measures used in this release to the most comparable U.S. GAAP measures for the respective periods can be found in a table later in this release immediately following the condensed consolidated statements of cash flows. Adjusted EBITDA should not be considered in isolation or as a substitute for a measure of the Company's liquidity or operating performance prepared in accordance with GAAP and is not indicative of operating income (loss) from operations as determined under GAAP. Adjusted EBITDA and other non-GAAP financial measures have limitations that should be considered before using these measures to evaluate the Company's liquidity or financial performance. Adjusted EBITDA does not include certain expenses that may be necessary to review LDR's operating results and liquidity requirements. Management's definition and calculation of Adjusted EBITDA may differ from that of other companies.

**Contacts:**

Robert McNamara

Executive Vice President and Chief Financial Officer

LDR Holding Corporation

(512) 344-3333

Bob Yedid

Managing Director

ICR, Inc.

(646) 277-1250

bob.yedid@icrinc.com

**LDR HOLDING CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(in thousands, except share amounts)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **March 31, 2014** | **March 31, 2014** |  |  | **December 31, 2013** | **December 31, 2013** |  |
|  |  | **Unaudited** | **Unaudited** |  |  |  |  |  |
| **ASSETS** |  |  |  |  |  |  |  |  |
| Current assets: |  |  |  |  |  |  |  |  |
| Cash and cash equivalents |  | $ | 49,840 |  |  | $ | 56,678 |  |
| Accounts receivable, net |  | 22,325 | 22,325 |  |  | 22,193 | 22,193 |  |
| Inventory, net |  | 20,781 | 20,781 |  |  | 17,690 | 17,690 |  |
| Other current assets |  | 6,234 | 6,234 |  |  | 4,780 | 4,780 |  |
| Prepaid expenses |  | 1,454 | 1,454 |  |  | 1,593 | 1,593 |  |
| Deferred tax asset, current |  | 515 | 515 |  |  | — | — |  |
| Total current assets |  | 101,149 | 101,149 |  |  | 102,934 | 102,934 |  |
| Property and equipment, net |  | 13,071 | 13,071 |  |  | 12,695 | 12,695 |  |
| Goodwill |  | 6,621 | 6,621 |  |  | 6,621 | 6,621 |  |
| Intangible assets, net |  | 3,143 | 3,143 |  |  | 3,073 | 3,073 |  |
| Restricted cash |  | 2,000 | 2,000 |  |  | 2,000 | 2,000 |  |
| Deferred tax assets |  | — | — |  |  | 513 | 513 |  |
| Other assets |  | 152 | 152 |  |  | 157 | 157 |  |
| Total assets |  | $ | 126,136 |  |  | $ | 127,993 |  |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |  |  |  |  |  |  |
| Current liabilities: |  |  |  |  |  |  |  |  |
| Current portion of long-term debt |  | $ | 1,609 |  |  | $ | 1,763 |  |
| Line of credit, net of discount |  | — | — |  |  | 18,162 | 18,162 |  |
| Accounts payable |  | 9,932 | 9,932 |  |  | 8,128 | 8,128 |  |
| Accrued expenses |  | 17,034 | 17,034 |  |  | 16,324 | 16,324 |  |
| Short-term financing |  | 965 | 965 |  |  | 2,641 | 2,641 |  |
| Deferred tax liabilities |  | — | — |  |  | 540 | 540 |  |
| Total current liabilities |  | 29,540 | 29,540 |  |  | 47,558 | 47,558 |  |
| Line of credit, net of discount |  | 18,165 | 18,165 |  |  | — | — |  |
| Long-term debt, net of discount and current portion |  | 2,427 | 2,427 |  |  | 2,758 | 2,758 |  |
| Deferred tax liabilities |  | 623 | 623 |  |  | — | — |  |
| Total liabilities |  | 50,755 | 50,755 |  |  | 50,316 | 50,316 |  |
| Commitments and contingencies |  |  |  |  |  |  |  |  |
| Stockholders' equity: |  |  |  |  |  |  |  |  |
| Common stock |  | 24 | 24 |  |  | 24 | 24 |  |
| Additional paid-in capital |  | 162,467 | 162,467 |  |  | 161,216 | 161,216 |  |
| Accumulated other comprehensive income |  | 150 | 150 |  |  | 198 | 198 |  |
| Accumulated deficit |  | (87,260 | (87,260 | ) |  | (83,761 | (83,761 | ) |
| Total stockholders' equity |  | 75,381 | 75,381 |  |  | 77,677 | 77,677 |  |
| Total liabilities and stockholders' equity |  | $ | 126,136 |  |  | $ | 127,993 |  |

**LDR HOLDING CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS**

**(in thousands, except share and per share amounts)**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |  |  |  |
|  |  | **2014** | **2014** |  |  | **2013** | **2013** |  |
| Revenue |  | $ | 31,068 |  |  | $ | 25,842 |  |
| Cost of goods sold |  | 5,256 | 5,256 |  |  | 4,299 | 4,299 |  |
| Gross profit |  | 25,812 | 25,812 |  |  | 21,543 | 21,543 |  |
| Operating expenses: |  |  |  |  |  |  |  |  |
| Research and development |  | 3,394 | 3,394 |  |  | 2,329 | 2,329 |  |
| Sales and marketing |  | 18,915 | 18,915 |  |  | 15,254 | 15,254 |  |
| General and administrative |  | 6,522 | 6,522 |  |  | 4,238 | 4,238 |  |
| Total operating expenses |  | 28,831 | 28,831 |  |  | 21,821 | 21,821 |  |
| Operating loss |  | (3,019 | (3,019 | ) |  | (278 | (278 | ) |
| Other operating income (expense): |  |  |  |  |  |  |  |  |
| Other income (expense) |  | (41 | (41 | ) |  | 461 | 461 |  |
| Interest income |  | — | — |  |  | 4 | 4 |  |
| Interest expense |  | (282 | (282 | ) |  | (1,002 | (1,002 | ) |
| Accretion related to warrants and discounts on long-term debt |  | — | — |  |  | (507 | (507 | ) |
| Change in fair value of common stock warrants |  | — | — |  |  | (277 | (277 | ) |
| Total other income (expense), net |  | (323 | (323 | ) |  | (1,321 | (1,321 | ) |
| Loss before income taxes |  | (3,342 | (3,342 | ) |  | (1,599 | (1,599 | ) |
| Income tax expense |  | (157 | (157 | ) |  | (288 | (288 | ) |
| Net loss |  | (3,499 | (3,499 | ) |  | (1,887 | (1,887 | ) |
| Other comprehensive loss: |  |  |  |  |  |  |  |  |
| Foreign currency translation |  | (48 | (48 | ) |  | (758 | (758 | ) |
| Comprehensive loss |  | $ | (3,547 | ) |  | $ | (2,645 | ) |
| Net loss per common share: |  |  |  |  |  |  |  |  |
| Basic and diluted |  | $ | (0.15 | ) |  | $ | (0.41 | ) |
| Weighted average number of shares outstanding: |  |  |  |  |  |  |  |  |
| Basic and diluted |  | 24,083,796 | 24,083,796 |  |  | 4,658,453 | 4,658,453 |  |

**LDR HOLDING CORPORATION AND SUBSIDIARIES**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(in thousands)**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |  |  |  |
|  |  | **2014** | **2014** |  |  | **2013** | **2013** |  |
| Operating activities: |  |  |  |  |  |  |  |  |
| Net loss |  | $ | (3,499 | ) |  | $ | (1,887 | ) |
| Adjustments to reconcile net loss to cash used in operating activities: |  |  |  |  |  |  |  |  |
| Bad debt expense |  | 202 | 202 |  |  | 12 | 12 |  |
| Provision for excess and obsolete inventories |  | 424 | 424 |  |  | 363 | 363 |  |
| Depreciation and amortization |  | 959 | 959 |  |  | 957 | 957 |  |
| Stock-based compensation |  | 1,040 | 1,040 |  |  | 66 | 66 |  |
| Accretion related to warrants and discounts on long-term debt |  | 6 | 6 |  |  | 507 | 507 |  |
| Change in fair value of common stock warrants |  | — | — |  |  | 277 | 277 |  |
| Deferred income tax expense (benefit) |  | 92 | 92 |  |  | — | — |  |
| Loss on disposal of assets |  | 105 | 105 |  |  | 3 | 3 |  |
| Unrealized foreign currency loss (gains) |  | (53 | (53 | ) |  | (500 | (500 | ) |
| Changes in operating assets and liabilities: |  |  |  |  |  |  |  |  |
| Accounts receivable |  | (316 | (316 | ) |  | (2,439 | (2,439 | ) |
| Prepaid expenses and other current assets |  | (1,138 | (1,138 | ) |  | (377 | (377 | ) |
| Inventory |  | (3,523 | (3,523 | ) |  | (639 | (639 | ) |
| Other assets |  | 3 | 3 |  |  | 29 | 29 |  |
| Accounts payable |  | 1,819 | 1,819 |  |  | (1,944 | (1,944 | ) |
| Accrued expenses |  | (679 | (679 | ) |  | 2,103 | 2,103 |  |
| Other long-term liabilities |  | — | — |  |  | 340 | 340 |  |
| Net cash used in operating activities |  | (4,558 | (4,558 | ) |  | (3,129 | (3,129 | ) |
| Investing activities: |  |  |  |  |  |  |  |  |
| Proceeds from sale of property and equipment |  | — | — |  |  | 23 | 23 |  |
| Purchase of intangible assets |  | (179 | (179 | ) |  | (94 | (94 | ) |
| Purchase of property and equipment |  | (1,487 | (1,487 | ) |  | (613 | (613 | ) |
| Net cash used in investing activities |  | (1,666 | (1,666 | ) |  | (684 | (684 | ) |
| Financing activities: |  |  |  |  |  |  |  |  |
| Proceeds from Employee Stock Purchase Plan |  | 1,354 | 1,354 |  |  | — | — |  |
| Exercise of stock options |  | 211 | 211 |  |  | 162 | 162 |  |
| Payments on capital leases |  | (13 | (13 | ) |  | (8 | (8 | ) |
| Net proceeds (payments) on short-term financings |  | (1,652 | (1,652 | ) |  | (9 | (9 | ) |
| Payments on long-term debt |  | (470 | (470 | ) |  | (468 | (468 | ) |
| Net cash used in financing activities |  | (570 | (570 | ) |  | (323 | (323 | ) |
| Effect of exchange rate on cash |  | (44 | (44 | ) |  | (32 | (32 | ) |
| Net change in cash and cash equivalents |  | (6,838 | (6,838 | ) |  | (4,168 | (4,168 | ) |
| Cash and cash equivalents, beginning of period |  | 56,678 | 56,678 |  |  | 19,135 | 19,135 |  |
| Cash and cash equivalents, end of period |  | $ | 49,840 |  |  | $ | 14,967 |  |

**LDR HOLDING CORPORATION AND SUBSIDIARIES**

**RECONCILIATION OF OPERATING LOSS TO NON-GAAP FINANCIAL MEASURES**

**(in thousands, except per share amounts)**

**(Unaudited)**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |  |  |  |  |  |
|  |  | **2014** | **2014** |  |  | **2013** | **2013** |  |
| Operating loss, as reported |  | $ | (3,019 | ) |  | $ | (278 | ) |
| Add back: |  |  |  |  |  |  |  |  |
| Depreciation and amortization |  | 959 | 959 |  |  | 957 | 957 |  |
| Stock-based compensation |  | 1,040 | 1,040 |  |  | 66 | 66 |  |
| Non-GAAP adjusted EBITDA |  | $ | (1,020 | ) |  | $ | 745 |  |
| Non-GAAP adjusted EBITDA margin |  | (3.3 | (3.3 | )% |  | 2.9 | 2.9 | % |